Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates by Fustolo-Gunnink, Susanna F et al.
  
 University of Groningen
Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates
Fustolo-Gunnink, Susanna F; Fijnvandraat, Karin; Putter, Hein; Ree, Isabelle M; Caram-






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Fustolo-Gunnink, S. F., Fijnvandraat, K., Putter, H., Ree, I. M., Caram-Deelder, C., Andriessen, P., ... van
der Bom, J. G. (2019). Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates.
Haematologica, 104(11), 2300-2306. https://doi.org/10.3324/haematol.2018.208595
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 19-05-2020
Dynamic prediction of bleeding risk in thrombocytopenic
preterm neonates
by Susanna F. Fustolo-Gunnink, Karin Fijnvandraat, Hein Putter, Isabelle M. Ree, Camila
Caram-Deelder, Peter Andriessen, Esther J. d'Haens, Christian V. Hulzebos, Wes Onland,
André A. Kroon, Daniël C. Vijlbrief, Enrico Lopriore, and Johanna G. van der Bom 
Haematologica 2019 [Epub ahead of print]
Citation: Susanna F. Fustolo-Gunnink, Karin Fijnvandraat, Hein Putter, Isabelle M. Ree, Camila
Caram-Deelder, Peter Andriessen, Esther J. d'Haens, Christian V. Hulzebos, Wes Onland, André A.
Kroon, Daniël C. Vijlbrief, Enrico Lopriore, and Johanna G. van der Bom. Dynamic prediction of 




E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2019 Ferrata Storti Foundation.





Full title: Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates 
Short title: Predicting bleeding in thrombocytopenic neonates.  
 
Susanna F. Fustolo-Gunnink,1-2 Karin Fijnvandraat,2-3 Hein Putter,4  Isabelle M. Ree,5 Camila Caram-Deelder,1 Peter 
Andriessen,6 Esther J. d’Haens,7 Christian V. Hulzebos,8 Wes Onland,9 André A. Kroon,10 Daniël C. Vijlbrief,11 Enrico 
Lopriore,5 and Johanna G. van der Bom.1-12    
1 Sanquin Research, Center for Clinical Transfusion Research, Plesmanlaan 1A, 2333 BZ Leiden, the Netherlands 
2 Amsterdam University Medical Center, Emma Children’s Hospital, department of pediatric hematology, Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, the 
Netherlands 
3Sanquin Blood Supply Foundation, Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands. 
4Leiden University Medical Center, department of medical statistics, Einthovenweg 20, 2333 ZC Leiden, the Netherlands 
5Leiden University Medical Center, Willem Alexander Children’s hospital, department of neonatology, Albinusdreef 2, 2333 ZA Leiden, the Netherlands 
6Máxima Medical Center, department of neonatology, De Run 4600, 5504 DB Veldhoven, the Netherlands 
7Isala Zwolle, Amalia Children’s center, department of neonatology, Dokter van Heesweg 2, 8025 AB Zwolle, the Netherlands 
8University Medical Center Groningen, Beatrix Children’s hospital, department of neonatology, Hanzeplein 1, 9713 GZ Groningen, the Netherlands 
9Amsterdam University Medical Center, Emma Children’s hospital, department of neonatology, Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, the Netherlands 
10Erasmus Medical Center, Sophia Children’s hospital, department of neonatology, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands 
11University Medical Center Utrecht, Utrecht University,Wilhelmina Children’s hospital, department of neonatology, Lundlaan 6, 3584 EA Utrecht, the 
Netherlands 
12Leiden University Medical Center, department of Clinical Epidemiology, Albinusdreef 2, 2333 ZA Leiden, the Netherlands. 
 
Corresponding author: J.G. van der Bom. Address: Sanquin Research, Center for  Clinical Transfusion Research, 
Plesmanlaan 1A, 2333 BZ Leiden, the Netherlands. Email: J.G.van_der_Bom@lumc.nl. Phone number: +31 71 
5268871. No fax number available.  
 
Abstract word count:  229 
Text word count:  2698 
Tables:   4  
Figures:   4 
References:   24 




Over 75% of severely thrombocytopenic neonates receive platelet transfusions, though little evidence supports 
this practice, and only 10% develop major bleeding. In a recent randomized trial, platelet transfusions given at a 
threshold of 50x109/L compared to a threshold of 25x109/L were associated with increased risk of major 
bleeding or mortality. These results emphasize the need for improved and individualized neonatal platelet 
transfusion guidelines, which require accurate prediction of bleeding risk. Therefore, the objective of this study 
was to develop a dynamic prediction model for major bleeding in thrombocytopenic preterm neonates. This 
model allows for calculation of bleeding risk at any time-point during the first week after onset of severe 
thrombocytopenia.   
In this multicenter cohort study, we included neonates with a gestational age <34 weeks, admitted to a neonatal 
intensive care unit, who developed severe thrombocytopenia (platelet count <50x109/L). The study endpoint was 
major bleeding. We obtained predictions of bleeding risk using a proportional baselines landmark supermodel. 
Of 640 included neonates, 71 (11%) developed major bleeding. We included the variables gestational age, 
postnatal age, intra-uterine growth restriction, necrotizing enterocolitis, sepsis, platelet count and mechanical 
ventilation in the model. The median cross-validated c-index was 0.74 (IQR 0.69-0.82).  
This is a promising dynamic prediction model for bleeding in this population that should be explored further in 





Neonatal major bleeding occurs in approximately 5-15% of preterm neonates admitted to a neonatal intensive 
care unit (NICU) and can lead to lifelong disabilities and death. The most common type of bleeding is 
intraventricular hemorrhage (IVH).1,2  
Since platelets are required for primary hemostasis, preterm neonates with severe thrombocytopenia are thought 
to be particularly at risk for major bleeding. However, the associations between thrombocytopenia, platelet 
transfusions and bleeding in preterm neonates are not clear. In a recently published systematic review, only six 
studies could be included. These provided insufficient evidence to assess whether platelet counts are causally 
related to major bleeding, or whether platelet transfusions reduce bleeding risk in thrombocytopenic preterm 
neonates.3 Despite this lack of evidence, platelet transfusions are given to approximately 75% of 
thrombocytopenic preterm neonates.4,5 
Recently, the first randomized trial assessing currently used platelet count thresholds in preterm infants was 
published. It showed that a prophylactic transfusion threshold of 50x109/L was associated with increased risk of 
bleeding and mortality compared to a lower threshold of 25x109/L, within 28 days after randomisation.6 These 
results emphasize the need for improved and individualized neonatal platelet transfusion guidelines. 
In addition to lack of evidence regarding transfusion thresholds and identification of platelet transfusion related 
harm, indications for platelet transfusions are based primarily on platelet count. However, two neonates with 
similar platelet counts but different clinical conditions may have a very different risk of bleeding, and benefit 
differently from platelet transfusions.7 We need to be able to predict which neonates will develop major bleeding 
and quantify this bleeding risk, using a model that includes not only platelet count but also a set of relevant 
clinical variables. This prediction model could be used to define indications for transfusion in future studies, 
which is a first step towards individualized platelet transfusion therapy.  
Some prediction models for bleeding in neonates have already been developed, but these models were not 
derived specifically for neonates with thrombocytopenia, and only allow for a risk assessment at baseline.8–15 
The disadvantage of baseline prediction models is that they do not take the clinical course of the neonate into 
account, which can change substantially over time, and may have a profound impact on bleeding risk. In 
dynamic prediction, the clinical course can be incorporated into the model. Therefore, the objective of this study 




The study protocol was published online on www.clinicaltrials.gov (NCT03110887). The institutional review 
board of the Academic Medical Center Amsterdam approved the study and waived the need for informed 
consent. The study was conducted in accordance with the Declaration of Helsinki and reported according to The 
Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) 
guidelines.16 An extended methods section is available in the Supplementary Materials, including the procedure 
for predictor selection, outcome definitions, a list of participating centers with an overview of clinical practice, 
description of the data acquisition process, sample size calculations, details on statistical methods and the role of 
the funding source.   
Population 
We performed a cohort study among consecutive preterm neonates with thrombocytopenia admitted to any one 
of seven participating NICU’s in the Netherlands between January 2010 and January 2015. The cohort 
comprised all neonates with gestational age at birth < 34 weeks and at least one platelet count < 50x109/L. We 
excluded patients with 1) severe congenital malformations; 2) a high suspicion of spurious platelet count (e.g. 
clots in the sample, or spontaneous platelet count recovery within six hours, or a platelet count labelled as 
spurious in the medical file); 3) thrombocytopenia occurring exclusively in the context of exchange transfusion; 
4) prior admission to another NICU or readmission, and 5) major bleeding prior to severe thrombocytopenia. 
Neonates with major bleeding after end of follow up were not excluded, but registered as not having experienced 
major bleeding during the study. 
Model development and statistics 
The core research team drafted and approved a statistical analysis plan prior to data analysis. We developed a 
proportional baselines landmark supermodel, with bleeding within the next three days as outcome.17 Variables 
included in the model were gestational age, intra uterine growth retardation (IUGR), mechanical ventilation, 
platelet count, platelet transfusion, postnatal age at inclusion, and necrotizing enterocolitis (NEC) and/or sepsis 
(combined).  
Model validation 
We validated the model by internal calibration using the heuristic shrinkage factor by van Houwelingen et al.18 
We evaluated the model’s accuracy in correctly discriminating between patients with and without major bleeding 
using the dynamic cross-validated c-index. A c-index of 1.0 indicates perfect discrimination, while a c-index of 
0.5 is obtained when the model performs as well as chance. We calculated a c-index at each two hour timepoint, 
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and reported this series of c-indices as a graph. Analyses were carried out using SPSS (version 24.0), Stata 
(version 14.1) and R (version 3.4.2). 
Clinical applicability of the model 
Our study is a first, basic prediction model for major bleeding in preterm neonates with severe 
thrombocytopenia. Due to the dynamic nature of the model, it cannot be fully summarized in one table, but once 
validation studies have been performed, we will develop an online calculator. We have chosen not to publish the 
calculator along with this paper, in order to prevent inappropriate premature use of the model in clinical practice. 





Of 9333 neonates with a gestational age <34 weeks, 927 had at least one platelet count <50x109/L. Of these, 67 
were excluded due to spurious platelet count and 29 because thrombocytopenia occurred only during a 
readmission. Of the remaining 831 neonates, 191 were excluded based on major bleeding prior to 
thrombocytopenia (55), previous admission to other NICU (51), congenital malformations (47), missing medical 
files (35) and because thrombocytopenia occurred exclusively during exchange transfusion (3). The remaining a 
640 neonates (7%) were included in the study. (Figure 1) The median gestational age at birth was 28.1 weeks 
and median birth weight was 900 grams (Table I and Figure S1 and S2). 73% of neonates received at least one 
platelet transfusion. No cases of fetal and neonatal alloimmune thrombocytopenia (FNAITP) were identified. 
Lowest platelet counts during study for neonates with and without major bleed are reported in Figure S3. 
Major bleeds 
A total of 71 (11%) major bleeds occurred, of which 55 were intraventricular hemorrhages and other 
intracerebral hemorrhages, twelve were pulmonary hemorrhages and four were gastro-intestinal hemorrhages 
(Table II). The major bleeds occurred at a median of  1 day (interquartile range 1-4) after onset of severe 
thrombocytopenia. At the end of the ten day follow up period, 73 patients (11%) had died, 63 (10%) had 
developed major bleeding and 93 (15%) had been discharged or transferred (Figure 2). Of the 93 discharged 
neonates, 76 (82%) were discharged to a stepdown unit. 91% of neonates underwent at least one ultrasound scan, 
with a mean of two scans during the ten days follow up period. In four neonates, major intracranial hemorrhage 
was already diagnosed on the first ultrasound scan after birth, on the first day of life. 
Model development 
The model contained 12 variables: all seven selected variables, plus the interaction term between platelet count 
and transfusion, plus interactions between time and IUGR and time and platelet count (both linear and 
quadratic). Platelet count was converted to a log-scale. The number of major bleeds included in the model was 
63, because eight bleeds occurred more than ten days after T0 (Table II).  
Final model 
The median c-index of the final model was 0.74 (interquartile range 0.69 - 0.82) (figure 3). This indicates good 
predictive performance. An example of a risk-estimation by the model is shown in Figure 4, a plot of bleeding 
risk of two neonates with a distinct risk profile. During study day 1-3, the predicted risk of major bleeding within 
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the next 3 days in Child A is substantially higher than in Child B, indicating that use of this prediction model 
during that time-period would have correctly identified Child A as being at high risk of bleeding. This image 
also illustrates that bleeding risk can increase or decrease rapidly. Table III shows the details of the model. A 
hazard ratio > 1 indicates that increase of the risk factor is associated with higher risk of bleeding, and a hazard 
ratio < 1 indicates that increase of the risk factor is associated with lower risk of bleeding. The effects of platelet 
count and IUGR varied over time, while the effects of all other variables were constant over time. Table IV 
shows predicted risks of bleeding for different clinical scenarios. 
Sensitivity analyses 
None of the sensitivity analyses resulted in substantial changes in hazard ratios for the individual covariates, 




In this study, we developed a dynamic prediction model for major bleeding in thrombocytopenic preterm 
neonates. The model has good predictive performance with a median c-index of 0.74.  
 
To our knowledge, this is the first dynamic prediction model for bleeding in preterm neonates. The importance 
of using a dynamic model is illustrated by a recent survey assessing at which thresholds clinicians would 
administer a platelet transfusion to a preterm neonate with a gestational age of 27 weeks at birth.19 The study 
showed that if this neonate was two days old and in stable condition, most (European) clinicians would transfuse 
at a threshold of 30x109/L. However, if the same neonate was septic, mechanically ventilated and receiving 
vasopressors, most clinicians would transfuse at a threshold of 50x109/L. This illustrates that although neonates 
may have a comparable clinical status at baseline (gestational age 27 weeks), their clinical course in the 
following days is perceived as an important determinant of bleeding risk. We have developed a model that 
allows clinicians to quantify bleeding risk and adjust it as the clinical situation of the neonate changes.  
 
Future validation studies should externally validate and preferably expand the model, to improve its predictive 
accuracy. Once a larger, externally validated model has been developed, it can be used to study the effect of 
platelet transfusion indications based on predicted risk of bleeding in an impact study. Ultimately, this is a first 
step towards individualized platelet transfusion guidelines. Individualized guidelines are important, because 
several studies have shown that there is a large discrepancy between the number of thrombocytopenic neonates 
receiving platelet transfusions (75%) and the number of neonates who develop major bleeding (9%).5,20 These 
numbers are comparable to our results, where 70% of neonates received transfusions and 11% developed major 
bleeding. In addition, results of a recent randomized trial indicate platelet transfusion related harm when using a 
platelet count threshold of 50x109/L compared to 25x109/L. Although the overall results of this study show 
benefit associated with the low threshold, not all neonates in the high threshold group developed major bleeding 
or died. Moreover, 19% of neonates in the low threshold group died or developed major bleeding. This indicates 
that a platelet count based transfusion threshold does not accurately separate neonates whose bleeding or death 
will be prevented by a platelet transfusion. A threshold that includes clinical variables, such as one based on our 




It is important to note that individual covariates in the model should not be interpreted as causal associations, 
because the associations may be confounded in multiple ways. For example, IUGR was associated with lower 
predicted bleeding risk in our model, but we cannot conclude that IUGR protects against bleeding. Firstly, 
because IUGR is also a risk factor for thrombocytopenia, and we restricted our population to neonates with 
thrombocytopenia. It is possible that other causes of thrombocytopenia, for example viral infections, are 
associated with higher risk of bleeding than IUGR. A neonate with thrombocytopenia as a result of IUGR is 
therefore not protected by IUGR, but has lower bleeding risk because the thrombocytopenia was not caused by a 
viral infection. This is an epidemiological concept called collider stratification bias.21 Secondly, perhaps 
neonates with IUGR received more treatments intended to decrease risk of bleeding as compared to neonates 
without IUGR, as neonatologists perceived them to be at higher risk of bleeding (confounding by indication). 
And lastly, because the number of events in our study was limited, we have not been able to correct for all 
possible confounders. In short, the association between IUGR and bleeding is complex, our model only indicates 
that it is a good predictor for bleeding, but we cannot draw any causal conclusion based on this information. This 
applies to all individual covariates in the model. 
 
Various possible limitations of our study need to be discussed. Firstly, we could not externally validate our 
model because a similar database is currently not available. Secondly, identification of prognostic variables 
could possibly have been improved with a prior systematic review assessing all potential predictors. However, 
despite this limitation, our model contains variables generally considered best candidates for predicting major 
bleeding, as many of them were included in various existing baseline models. Some variables, such as mean 
platelet volume and immature platelet count, could not be included in our model because they were not routinely 
measured. Thirdly, the time a major bleed occurs is not similar to the time it is diagnosed on an ultrasound scan, 
because major intracranial bleeds in neonates are often asymptomatic, and detected during routine screening. To 
address this issue, we performed two additional sensitivity analyses, one in which we corrected time of bleeding 
based on whether or not minor bleeding was visible on prior ultrasound scans, and one in which we removed 
events of which we could not determine whether they occurred prior to or after the bleeding. Results of these 
analyses showed minor changes in hazard ratios of individual coefficients, suggesting that this problem does not 
substantially affect the predictive power of our model (Table SIII). Fourthly, after day six, the c-index drops 
below 0.60, possibly due to a lower event rate, therefore the model should be applied with caution after day six. 
We hypothesize that the variation in predictive accuracy over time as depicted in figure 2 may be caused by a 
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balance between having enough clinical information to predict (difficult on day 1 and 2), and enough events to 
fit a good model (difficult after day 4). Fifthly, the risk of bleeding in neonates in our population may have been 
affected by treatment with platelet transfusions. Therefore, the risks calculated using our model may be an 
underestimation of the ‘true’ risk (without transfusion). However, there are no cohorts available in which platelet 
transfusions were not administered and various studies including the previsouly described randomized controlled 
trial suggest that the effect of platelet transfusions on bleeding risk may be limited.6,22–24 We therefore estimate 
that our model’s predictions are accurate. Finally, four neonates had a gestational age at birth of less than 24 
weeks. In addition, local policies differed with respect to active support for neonates born at a gestational age 
between 24+0 and 25+6 weeks. Therefore, the neonates with a gestational age less than 26 weeks in our 
population might be a selection of neonates for whom good outcomes were expected. The model should thus be 
applied with caution in neonates less than 26 weeks gestational age.  
 
Strengths of our study are the size of the cohort and the fact that we have selected the predictors prior to data 
analysis and have not performed stepwise selection. In addition, we have performed meticulous data collection 
and multiple additional sensitivity analyses to confirm the robustness of our model. Our model is easy to apply, 
because we have used clear and simple definitions of the covariates. Once the model has been externally 
validated, we will develop an online calculator, with which it should only take a few minutes to enter the 
variables and calculate absolute risk of bleeding.  
 
In short, this dynamic prediction model allows clinicians to quantify bleeding risk and adjust it as the clinical 
situation of the neonate changes. Risk can be predicted at any timepoint during the first week after onset of 
severe thrombocytopenia. This is a promising model that should be explored in future studies, as it is a first step 
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Table I. Baseline characteristics (N=640) 
 Total cohort 
(n=640) 
 Major bleed 
(n=71) 
 No major bleed 
(n=569) 
At birth         
Gestational age in weeks: median (IQR)1 28.1  (26.4-30.4)  27.7 (26.1-29.1)  28.1 (26.4-30.6) 
Birth weight in grams: median (IQR) 900  (710-1180)  945 (760-1200)  900 (705-1178) 
Intra uterine growth retardation, n (%) 206  (32)  14 (20)  192 (34) 
At onset of severe thrombocytopenia         
Postnatal age in days: median (IQR) 3.9  (1.6-9.25)  2.6 (1.0-6.8)  4.1 (1.8-9.8) 
Platelet count x109/L, median (IQR) 38  (29-45)  39 (31-44)  38 (28-45) 
Mechanical ventilation, n (%) 329  (51)  49 (69)  280 (49) 
Necrotizing enterocolitis/sepsis, n (%) 
  Sepsis, n (%) 



















IQR = interquartile range.  
1




Table II. Types of  bleeding  
Major bleeds, n (%) 71  (11) 
Type of major bleeding, n (%)   
Uni-/bilateral IVH grade 3 with or without parenchymal involvement 32 (45) 
IVH grade 1 or 2 (uni- or bilateral) with parenchymal involvement 4 (6) 
Solitary (non-cerebellar) parenchymal hemorrhage 4 (6) 
Cerebellar parenchymal hemorrhage 11 (15) 
Subdural hemorrhage 4 (6) 
Pulmonary hemorrhage 12 (17) 
Gastrointestinal hemorrhage 4 (6) 
Eight bleeds (of 71) were excluded from the model because they occurred more than ten  days after T0.: 1 cerebellar, 1 
IVH grade 1 plus infarction basal ganglia, 1 IVH grade 1 and grade 2 plus infarction basal ganglia, 1 gastro-intestinal 
bleed, 1 pulmonary bleed, 1 bilateral IVH grade III, 1 frontal-parietal bleed and 1 subdural hemorrhage. 






Table III. The dynamic prediction model  
  Hazard ratio 95% CI 
Covariates with time-constant effects 
Gestational age (days)  1.00 0.98 – 1.02 
Postnatal age (days)  0.88 0.83 – 0.94* 
Mechanical ventilation  5.08 2.03 – 10.65* 
NEC/sepsis  0.85 0.43 – 1.58 
Platelet transfusion  1.06 0.38 – 2.95 
Interaction term log10 platelet count and 
platelet transfusion 
 1.23 0.63 – 2.38 
Covariates with time-varying effects 
LM (2 hour intervals)  2.30 0.89 – 5.94 
LM2 (2 hour intervals)  0.85 0.74 – 0.98* 
IUGR Constant 
IUGR Time-varying: LM 




0.17 – 1.59 
0.09 – 1.14 
1.04 – 1.44* 
Log10 platelet count Constant 
Log10 platelet count Time-varying LM 




0.72 – 4.24 
0.19 – 0.63* 
1.03 – 1.21* 
A hazard ratio > 1 indicates that increase of the risk factor is associated with higher risk of 
bleeding. E.g. a mechanically ventilated neonate has a 5.08 times higher bleeding risk than a 
neonate who is not mechanically ventilated.   
CI = confidence interval. If both ends of the confidence interval are either higher than 1 or lower 
than 1, the variable is a statistically significant predictor, indicated by *. LM = landmark time, 
linear interaction. LM2 = landmark time, quadratic interaction. LM or landmark time refers to time 
since onset of severe thrombocytopenia (time-dependent variable), in 2 hour time intervals. 
Postnatal age refers to the postnatal age at the onset of severe thrombocytopenia (baseline 
variables).  
Time-varying covariates should not be confused with time-dependent covariates, such as platelet 
count or platelet transfusion, where the value of the variable is not fixed (it is not a baseline 
variable) but can change over time. In time-varying covariates, the effect of the covariate can 
change over time, for example, the strength and direction of a potential association of IUGR with 
bleeding could be different immediately after onset of thrombocytopenia compared to a few days 
after onset of thrombocytopenia, due to interactions with other risk factors and changes in the 




Table IV: Risk predictions for different clinical scenarios 
Patient characteristics: GA 28 weeks, platelet count 10x109/L at day 3 
of life (first time <50x109/L), no transfusion 
  Ventilation No ventilation 
NEC/sepsis IUGR 8% 2% 
No NEC/sepsis No IUGR 17% 3% 
NEC/sepsis No IUGR 14% 3% 
No NEC/sepsis IUGR 9% 2% 
 
Patient characteristics: GA 28 weeks, platelet count 50x109/L at day 3 
of life (first time <50x109/L) , no transfusion 
  Ventilation No ventilation 
NEC/sepsis IUGR 11% 2% 
No NEC/sepsis No IUGR 24% 5% 
NEC/sepsis No IUGR 20% 4% 
No NEC/sepsis IUGR 13% 3% 





Legend figure 1: CONSORT flow chart. CONSORT = consolidated standards of reporting trials. NICU = 
neonatal intensive care unit. 
 
Legend figure 2: Number of neonates reaching the different study endpoints (major bleeding, death or 
discharge/transfer) in the first 10 days after the onset of severe thrombocytopenia. T0 is the day on which 
platelet counts dropped below 50x109/L for the first time. Neonates who developed a major bleeding and then 
died were only registered as major bleeding (no overlap between major bleeding and mortality). 
 
Legend figure 3: Dynamic, cross-validated c-index. This graph represents the dynamic, cross-validated c-index 
of the main model. A c-index of 1 resembles a model that discriminates perfectly between patients with and 
without a major bleeding, while a c-index of 0.5 indicates that the prediction is as good as chance. For each 
timepoint, the number at risk at the beginning of that day have been reported, as well as the total number of 
major bleeds that occurred during these 24 hours. E.g. at the start of day one, 604 patients were still at risk, and 
during this day 22 neonates developed a major bleed.  
 
Legend figure 4: Change in probability of developing a major bleeding within three days for two example 
patients. Day 0 is the day of onset of severe thrombocytopenia (T0). Characteristics of child A: gestational age 
(weeks+days) 27+2, birthweight 1100 grams, 2 days old at T0, sepsis, mechanical ventilation, 2 platelet 
transfusions, platelet counts 41-104-47-88 x109/L. Bilateral grade III IVH on day 2. Characteristics of child B: 
gestational age (weeks+days) 32+3, birth weight 1175 grams, 5 days old at T0, sepsis, no mechanical ventilation, 
no platelet transfusions, platelet counts 4-53-49-63-195-376 x109/L. No major bleed. Day 3-7 not shown because 
no substantial change in bleeding risk occurred. During study day 1-3, the predicted risk of major bleeding 
within the next 3 days in Child A is substantially higher than in Child B, indicating that use of this prediction 
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 NR = not registered in medical files. NC = no contrast (risk factor present in <5% or >95% of population. NM= not measured. RA = rare 
event. TE = timing of event problematic. When event occurs after risk period for bleeding (e.g. BPD). CO = risk factor combined with other 
risk factor (e.g. hyperglycemia and glucose disorders). ND = risk factor not well defined. NA = no association with bleeding (checked in a 
selection of papers). OT = other. Grey highlights: variables selected for further review (n=74). 
2 
Supplementary materials 
Table S1: list of potential predictors identified in literature search (ranked by number of papers). 
Description  Code Number of 
papers 
mode of delivery  100 
gestational age  100 
antenatal corticosteroids  99 
birth weight  89 
anyything related to ventilation  87 
Apgar scores  62 
chorioamnionitis  60 
surfactant  59 
gender  57 
anything related to hemodynamics / shock  54 
patent ductus arteriosus  52 
preeclampsia  44 
includes ph, lactatae, BE, etc  44 
PROM  43 
sepsis  34 
postnatal corticosteroids  31 
respiratory distress syndrome  30 
platelets or platelet tx  29 
tocolysis  27 
multifetal pregnancies  27 
pneumothorax   23 
maternal age  22 
fetal heart rate reactivity NR 21 
doppler  20 
inotropic agents   20 
inborn versus outborn NC 18 
twins CO 16 
interhospital transport CO 16 
maternal bleeding  15 
fetal position (breech, vertex)  15 
indomethacin  15 
SGA CO 15 
Genes NM 15 
RBC transfusion  14 
antenatal magnesium  14 
resuscitation at birth  14 
ethnicity  13 
Mode of conception  13 
maternal sepsis  12 
IUGR CO 11 
maternal drugs  11 
Description  Code Number of 
papers 
sodiumbicarbonate CO 11 
necrotizing enterocolitis   11 
coagulation NM 11 
hematocrit   11 
body temperature  11 
maternal smoking   10 
parity   10 
postnatal doppler NM 10 
abruptio placentae RA 9 
phenobarbital RA 9 
interleukin 6 NM 9 
red blood cells  9 
nucleated red blood cells or erythroblasts  9 
suspected fetal distress  NR 8 
beginning of labor (induced, spontaneous)  8 
nitric oxide RA 8 
premature contractions CO 7 
timing of delivery   7 
intubation in delivery room  CO 7 
sodium  7 
white blood cell count   7 
clinical risk score for babies NR 7 
prenatal care NC 6 
maternal fever  CO 6 
ethamsylate RA 6 
triplets RA 6 
resuscitation  6 
seizures  6 
SNAP score NR 6 
abruptio placentae or placenta praevia RA 5 
chorionicity  5 
vitamin E RA 5 
pulmonary hemorrhage  5 
hypothermia CO 5 
placenta NM 4 
maternal diabetes  4 
maternal phenobarbital RA 4 
maternal alcohol use  4 
antenatal indomethacin  4 
meconium  4 
vitamin A RA 4 
 NR = not registered in medical files. NC = no contrast (risk factor present in <5% or >95% of population. NM= not measured. RA = rare 
event. TE = timing of event problematic. When event occurs after risk period for bleeding (e.g. BPD). CO = risk factor combined with other 
risk factor (e.g. hyperglycemia and glucose disorders). ND = risk factor not well defined. NA = no association with bleeding (checked in a 
selection of papers). OT = other. Grey highlights: variables selected for further review (n=74). 
3 
Description  Code Number of 
papers 
erythropoietin RA 4 
opioids  4 
hyperglycemia CO 4 
periventricular leukomalacia TE 4 
thyroid RA 4 
ureaplasma infection CO 4 
gravida  4 
blood glucose disorders  4 
typecaregiver NR 4 
NIRS en FTOE (fractional tissue oxygen 
extraction) 
NM 4 
intraventricular hemorrhage OT 4 
vena cava superior flow NM 4 
ECMO RA 4 
umbilical line placement NC 4 
maternal aspirin RA 3 
maternal vitamin K RA 3 
maternal race NR 3 
fetal heart rate monitoring NR 3 
birth asphyxia  3 
interval between fetuses in multifetal 
pregnancy 
RA 3 
active labor NR 3 
duration of labor NR 3 
heparin RA 3 
activin A NM 3 
bilirubin NC 3 
neutropenia CO 3 
infectious agents  3 
potassium  3 
C-reactive protein  3 
repeat suctioning  NR 3 
EEG NM 3 
maternal SLE RA 2 
maternal asthma RA 2 
cerclage in triplet gestation RA 2 
HELLP CO 2 
maternal education  NR 2 
maternal infection as an indication for 
delivery 
CO 2 
placenta infarction RA 2 
idiopathic preterm labor CO 2 
maternal anaesthetics  2 
maternal socio economic status NR 2 
maternal use of 17-hydroxyprogesterone RA 2 
birth induction (iatrogenic preterm birth) CO 2 
Description  Code Number of 
papers 
umbilical cord clamping NR 2 
MOD triplet RA 2 
acidemia CO 2 
birthorder  2 
antihypertensives CO 2 
head circumference NC 3 
bronchopulmonary dysplasia TE 2 
apnea NR 2 
creatinemia NM 2 
insulin-like growth factor NM 2 
neonatal leukemoid reaction RA 2 
creatine kinase NM 2 
AST, LDH, CK, HBDS, ASAT etc NM 2 
interleukin 8 NM 2 
incubators NR 2 
type of NICU NC 2 
potential better practices NR 2 
nurse practicioner vs pediatric resident NR 2 
TTS RA 2 
clinical judgement (threatened, stable) NR 2 
recurrent apnoe / bradycardia NR 2 
maternal bethasone CO 1 
maternal magnesium sulfate and 
aminophylline 
RA 1 
maternal floor infarction RA 1 
maternal transplantation RA 1 
maternal hepatitis RA 1 
maternal beta sympathicomimetics RA 1 
maternal antiphospholipid syndrome RA 1 
perinatal care NC 1 
maternal toxemia  CO 1 
maternal genital tract flora NM 1 
amount of amniotic fluid  NC 1 
placenta weight  1 
placenta perfusion defect NM 1 
maternal medication  ND 1 
antenatal corticosteroids in combination 
with antibiotics 
CO 1 
maternal chronic disease (not specified) RA 1 
maternal pregnancy related disease CO 1 
cervical incompetence NR 1 
cervical cerclage RA 1 
amniocentesis RA 1 
PROM in combination with 
chorioamnionitis 
CO 1 
maternal drugs and smoking CP 1 
 NR = not registered in medical files. NC = no contrast (risk factor present in <5% or >95% of population. NM= not measured. RA = rare 
event. TE = timing of event problematic. When event occurs after risk period for bleeding (e.g. BPD). CO = risk factor combined with other 
risk factor (e.g. hyperglycemia and glucose disorders). ND = risk factor not well defined. NA = no association with bleeding (checked in a 
selection of papers). OT = other. Grey highlights: variables selected for further review (n=74). 
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Description  Code Number of 
papers 
history of abortion RA 1 
maternal epidural paincontrol CO 1 
maternal urinary tract infection CO 1 
previous adverse pregnancy outcome NR 1 
uncomplicated pregnancy NR 1 
maternal body mass index NR 1 
maternal weight gain NR 1 
maternal Hb NM 1 
maternal Ht NM 1 
maternal platelet NM 1 
mproteinuria CO 1 
idiopathic preterm labor or PROM CO 1 
cervical width on admission NR 1 
length of prepartum hospital stay NR 1 
maternal anti epileptics RA 1 
maternal trombocytopenia RA 1 
maternal serum thromboxane B2 
concentrations 
NM 1 
antenatal corticosteroids in combination 
with vit K 
NC 1 
PROM and oligohydramnios NR 1 
twinantcorts CO 1 
antcortstoco CO 1 
Other causes for preterm birth, (eg prenat 
diagn malformation)  
ND 1 
unknown cause of preterm birth CO 1 
fetal inflammatory response (placenta 
histology) 
CO 1 
biophysical profile  CO 1 
antenatal thyroid releasing hormone NM 1 
maternal hyperuricemia RA 1 
month of birth NA 1 
PPROM guideline NR 1 
bruising postpartum NR 1 
MOD in hemophilia RA 1 
umbilical cord abnormal   ND 1 
prolonged second stage of labor NR 1 
shoulder dystocia RA 1 
mode of labor  CO 1 
prolonged labor NR 1 
precipitous delivery (quick delivery, <3 
hours) 
NR 1 
unattended delivery RA 1 
placenta accreta plus meconium RA 1 
placenta infarction plus amnionitis RA 1 
prolapsed cord RA 1 
no spontaneous respiration at 5 min  1 
Description  Code Number of 
papers 
nuchalcord RA 1 
deliveryrisk ND 1 
homebirth RA 1 
DOB  1 
TOB  1 
wrap after birth for temperature control  1 
umbilical cord milking NR 1 
trial of labor after CS RA 1 
probiotics RA 1 
amphotericin RA 1 
EACA during ECMO RA 1 
emollient RA 1 
ascorbicacid RA 1 
alpha proteinase inhibitor RA 1 
immuneglobulins RA 1 
tranexamic acid RA 1 
ibuprofen  1 
docosahexaenoic acid  RA 1 
dopamin vs hydrocortison CO 1 
epinephrine  CO 1 
diuretics RA 1 
antibiotics  1 
opioids plus muscle relaxant RA 1 
musclerelaxants RA 1 
tolazoline RA 1 
alkali RA 1 
vitaminK NC 1 
ambroxol RA 1 
buffer RA 1 
analgesia RA 1 
fluconazol  1 
insulin RA 1 
macrosomy CO 1 
twin with 1 anomalous fetus RA 1 
congenital anomaly RA 1 
reduced multifetal pregnancy RA 1 
discordant twins (vs non-discordant) RA 1 
postconceptional age CO 1 
discordant triplets (vs non-discordant) RA 1 
meningitis RA 1 
pathological icterus (nieuwe variabele) NC 1 
diffuse intravascular coagulation  1 
retinopathy of prematurity TE 1 
pulmonary interstitial emphysema  CO 1 
 NR = not registered in medical files. NC = no contrast (risk factor present in <5% or >95% of population. NM= not measured. RA = rare 
event. TE = timing of event problematic. When event occurs after risk period for bleeding (e.g. BPD). CO = risk factor combined with other 
risk factor (e.g. hyperglycemia and glucose disorders). ND = risk factor not well defined. NA = no association with bleeding (checked in a 
selection of papers). OT = other. Grey highlights: variables selected for further review (n=74). 
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Description  Code Number of 
papers 
hypoglycemia CO 1 
pneumonia  1 
neonpulmcompl CO 1 
metalloprotease NM 1 
lymphocytes NM 1 
mannose-binding lectin NM 1 
hemopoietic stem cells NM 1 
Erythropoietine and interleukin 6  NM 1 
immune proteins and cytokines  NM 1 
Free radicals NM 1 
lactate and base excess CO 1 
genetic polymorphisms of antioxidant 
enzymes 
NM 1 
homocysteine NM 1 
ADAMTS13 NM 1 
paCO2 CO 1 
antioxidants NM 1 
antithrombin III NM 1 
enolase NM 1 
IL1a NM 1 
IL1b NM 1 
tumor necrosis factor NM 1 
osmolality NM 1 
calcium NM 1 
hypoxanthin NM 1 
xanthin NM 1 
VEGF NM 1 
adrenomedullin NM 1 
S100protein NM 1 
brain derived neurotrophic factor NM 1 
interleukin 12 NM 1 
nursing excellence NR 1 
after-hours in house senior physician cover NR 1 
environmental temperature NR 1 
organizational quality of NICU NR 1 
fetal vs neonatal growth charts OT 1 
height of NICU NC 1 
study participation OT 1 
individualized care NR 1 
outpatientcare CO 1 
outborn CO 1 
active IVH surveillance methods NR 1 
minimal handling NR 1 
IVH prevention protocol NR 1 
Description  Code Number of 
papers 
extubation CO 1 
biochemical pulmonary assessment NM 1 
paralysis during ventilation RA 1 
biochemical long maturity and gestational 
age 
NM 1 
irregular respiration NR 1 
fresh frozen plasma  1 
based on genetic mutations and 
homocysteine levels 
RA 1 
conjunctival hemorrhage RA 1 
retinal hemorrhage RA 1 
exchange transfusion RA 1 
plasmanate CO 1 
periventricular bleeding TE 1 
gastro-intestinal surgery OT 1 
rectal bleeds guideline NR 1 
vaccinations TE 1 
HELPP and Preterm CO 1 
MOD in triplets RA 1 
weight improvement program NR 1 
digital cervical examination  NR 1 
corticosteroids both antenatal and 
postnatal 
CO 1 
intrauterine myelomeningokele repair RA 1 
candida infection RA 1 
nasal CPAP + minimal handling NR 1 
influence of birth weight on bleeding risk 
during ECMO 
RA 1 
multiple risk factors for bleeding during 
ECMO 
RA 1 
cathether position NR 1 
renal injury in asphyxiated newborn 
infants 
RA 1 
enteral feeding NC 1 
antenatal and postnatal phenobarbital CO 1 
cardiac arrest before ECMO RA 1 
mode of ECMO RA 1 
breast milk NR 1 
bpm NR 1 
cardiac markers e.g. troponin, pro-BNP NM 1 
enrollment bias OT 1 
weight during ECMO RA 1 
consanguin parents NR 1 
age at intubation CO 1 
age at admission to NICU NC 1 
age at surfactant administration CO 1 
surgery OT 1 
congenital heart disease RA 1 
 NR = not registered in medical files. NC = no contrast (risk factor present in <5% or >95% of population. NM= not measured. RA = rare 
event. TE = timing of event problematic. When event occurs after risk period for bleeding (e.g. BPD). CO = risk factor combined with other 
risk factor (e.g. hyperglycemia and glucose disorders). ND = risk factor not well defined. NA = no association with bleeding (checked in a 
selection of papers). OT = other. Grey highlights: variables selected for further review (n=74). 
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Description  Code Number of 
papers 
chesttubes RA 1 
healthy versus entire population (BW 
curves study) 
OT 1 
full fontanel NR 1 
abnormal eye signs (e.g. nystagmus) NR 1 
decreased tone NR 1 
change in activity (spontaneous 
movement) 
NR 1 
abnormal movement or posture NR 1 
targeted neonatal echocardiography NM 1 
 NM 1 
fentanyl versus dexmedetomidine RA 1 
laboratory samples drawn from placenta vs 
baby 
NM 1 
neonatal resuscitation program team 
training 
NR 1 
NAITP RA 1 
enemas RA 1 
maternal BMI impact on triplets CO 1 
discordant doppler velocimetric findings 
in twins 
RA 1 
neonatal status score NR 1 
outpatient and chorioamnionitis  RA 1 
guideline for preeclampsia NR 1 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
7 
Table S2: additional information about the model variables. 
Variable Definition 
What was entered into the model at each 
landmark point 
Postnatal age Age in hours since time of birth Age in hours (baseline variable) 
Gestational age Gestational age as reported in medical files Gestational age in days (baseline variable) 
IUGR  
Birthweight below the 10th centile according to 
Dutch national birth weight curves 
IUGR yes/no (baseline variable) 
Mechanical 
ventilation 
A neonate was deemed as being mechanically 
ventilated when he or she was intubated, irrespective 
of ventilation type, ventilator settings and duration of 
ventilation. 
Mechanically ventilated yes/no 
Platelet count 
Every platelet count was recorded in the database as 
count x109/L.  
Most recent platelet count 
Platelet 
transfusion 
Every platelet transfusion was recorded in the 
database, including dose. 
Transfusion given within 2 hours after 
landmark point yes/no1 
NEC/sepsis 
(combined) 
NEC was defined as ≥ grade IIA as per Bell’s 
criteria.1 Sepsis was defined as culture positive sepsis 
or culture negative sepsis where antibiotics are given 
for a minimum of 5 complete days 
NEC/sepsis yes/no. If either NEC or sepsis, 
are present, answer yes.  
1 We included transfusion after, not before, the landmark point into the model, because we wanted clinicians to be able to 
calculate bleeding risk with and without giving a platelet transfusion. This could potentially induce immortal time bias, but 
since the time interval is relatively short compared to our prediction window (2 versus 72 hours), we deemed this risk 
negligible. We did not present this feature of the model in the main paper, because the combined hazard ratios of transfusion 
and the interaction term of transfusion and platelet count suggest that transfusions are associated with increased bleeding risk 
in all neonates. We hypothesise that this is partially caused by the fact that we did not adjust for all possible confounders, due 






Figure S1: lowest platelet count during study for neonates with and without major bleed. 
Legend figure S1. This scatterplot represents the lowest platelet count during study for neonates with and without major 
bleeding. For neonates with major bleeding, end of study was defined as the major bleed, therefore this platelet count 
represents the lowest platelet count prior to major bleeding. Lines represent median and interquartile ranges.  
Figure S2: gestational age at birth in neonates with and without major bleeding.  
 




Table S2: sensitivity analyses 1 
Name Description Results and interpretation 
Timing accuracy In our primary analysis, all variables were included irrespective of whether time 
of event was known exactly (+/- five minutes), or was estimated (range: +/- 30 
minutes to +/- 12 hours). In this sensitivity analysis, we only included patients if 
100% of their event times had a maximum uncertainty of +/- 30 minutes. 
This left 308 neonates in the model, with 41 major bleeds. Minor 
changes in covariate hazard ratios indicate that timing inaccuracies 
did not substantially influence our primary model. 
Major bleed plus 
mortality 
In our primary analysis, our outcome was major bleeding. In this sensitivity 
analysis, our outcome was a composite of major bleeding and mortality. 
136 neonates reached this composite endpoint within ten days after 
T0. Minor changes in covariate hazard ratios indicate that our model 
predicts a composite outcome of major bleeding and mortality as 
well as it predicts major bleeding alone. 
Model without 
grey areas 
In our primary model, events that occurred after an ultrasound that showed no 
major bleed, but prior to an ultrasound that showed a major bleed, the so-called 
grey area, were included. In this sensitivity analysis, we excluded those, 
because we could not know whether these happened prior to or after the bleed.  
Grey areas ranged from zero to ten days. Minor changes in covariate 
hazard ratios indicate that the uncertainty of the timing of events 
within these ‘grey area’s’ did not substantially influence our primary 
model. 
Revised start-time 
of major bleeding 
In our primary analysis, the time of major bleed was defined as the time on 
which a bleeding was classified as major for the first time. In this sensitivity 
analysis we looked at the ultrasounds prior to the major bleeding to see if the 
bleeding had already started (minor bleed on previous ultrasound scan). If so, 
we changed the time of major bleed accordingly. 
This left 635 neonates in the model, with 65 major bleeds. Minor 
changes in covariate hazard ratios indicate that improving our 




In our primary analysis, neonates reached end of study at time of discharge, 
death or major bleeding. In this sensitivity analysis, end of study is defined as 
the end of severe thrombocytopenia plus an additional three days, a window of 
time during which the effect of thrombocytopenia might still be present. 
This left 58 major bleeds in the model. Minor changes in covariate 
hazard ratios indicate that our model has good predictive power even 
after platelet counts return to normal. 
Landmarks every 
hour 
In our primary analysis, landmarks were set at every two hours. In this 
sensitivity analysis, landmarks were set at every hour, to assure accurateness of 
order of events (events prior to or after landmark points). 
Minor changes in covariate hazard ratios indicate that changing the 




Table S3: sensitivity analysis (continued)  1 
Sensitivity analysis model Timing accuracy 
Major bleed  
plus mortality 
Model without  
grey areas 
Revised start time  





Covariates with time-constant effects       
Gestational age (days) 1·01 (0·99 – 1·04 ) 0·99 (0·98 – 1·01) 1·00 (0·99 – 1·02) 1·00 (0·99 – 1·02) 1·01 (0·99 – 1·02) 1·00 (0·98 – 1·02) 
Postnatal age (days) 0·95 (0·89 – 1·01) 0·96 (0·93 – 1·00) 0·88 (0·82 – 0·94) 0·89 (0·84 – 0·95) 0·89 (0·84 – 0·94) 0·88 (0·83 – 0·94) 
Mechanical ventilation 7·47 (2·82 – 19·78) 3·87 (2·34 – 6·40) 4·43 (1·81 – 10·80) 4·82 (2·04 – 11·35) 5·29 (2·18 – 12·82) 4·18 (1·83 – 9·52) 
NEC/sepsis 0·86 (0·38 – 1·94) 0·72 (0·47 – 1·08) 0·89 (0·43 – 1·84) 0·72 (0·37 – 1·42) 0·81 (0·41 – 1·59) 0·80 (0·42 – 1·53) 
Platelet transfusion 0·58 (0·15 – 2·20) 0·55 (0·26 – 1·13) 0·39 (0·05 – 3·03) 0·88 (0·30 – 2·57) 1·10 (0·38 – 3·21) 1·05 (0·35 – 3·14) 
Interaction platelet count and transfusion 1·89 (0·78 – 4·56) 1·73 (1·06 – 2·82) 1·67 (0·46 – 6·00) 1·35 (0·67 – 2·72) 1·18 (0·59 – 2·37) 1·17 (0·57 – 2·42) 
       
Covariates with time-varying effects       
IUGR Constant 0·53 (0·14 – 1·97 ) 0·48 (0·23 – 0·99) 0·23 (0·05 – 1·04) 0·61 (0·21 – 1·77) 0·49 (0·16 – 1·52) 0·57 (0·20 – 1·68) 
IUGR Time-varying: LM 0·59 (0·19 – 1·86) 1·05 (0·59 – 1·87) 0·41 (0·09 – 1·82) 0·28 (0·09 – 0·93) 0·35 (0·11 – 1·08) 0·25 (0·08 – 0·85) 
IUGR Time-varying: LM2 1·10 (0·92 – 1·31) 1·01 (0·96 – 1·15) 1·21 (0·98 – 1·51) 1·26 (1·05 – 1·50) 1·21 (1·02 – 1·42) 1·28 (1·07 – 1·53) 
Log10 platelet count Constant 2·89 (0·66 – 12·56) 0·96 (0·43 – 2·11) 2·08 (0·65 – 6·64) 2·42 (0·9  – 6·44) 2·17 (0·76 – 6·15) 2·07 (0·84 – 5·14) 
Log10 platelet count Time-varying LM 0·24 (0·08 – 0·71) 0·44 (0·27 – 0·72) 0·37 (0·16 – 0·87) 0·25 (0·13 – 0·48) 0·28 (0·14 – 0·58) 0·28 (0·14 – 0·56) 
Log10 platelet count Time-varying: LM2 1·19 (1·00 – 1·41) 1·09 (1·03 – 1·17) 1·10 (0·98 – 1·23) 1·17 (1·06 – 1·30) 1·16 (1·03 – 1·30) 1·16 (1·05 – 1·29) 
Coefficients are expressed as hazard ratio (95% confidence interval). 2 
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Extended methods section 1 
 2 
The study protocol was published online on www.clinicaltrials.gov (NCT03110887). The institutional review 3 
board of the Academic Medical Center Amsterdam approved the study and waived the need for informed 4 
consent, since the study involves retrospective datacollection. The study was conducted in accordance with the 5 
Declaration of Helsinki and reported according to The Transparent Reporting of a Multivariable Prediction 6 
Model for Individual Prognosis or Diagnosis (TRIPOD) guidelines.2 7 
Population 8 
We performed a cohort study among consecutive preterm neonates with thrombocytopenia admitted to any one 9 
of seven participating NICU’s in the Netherlands between January 2010 and January 2015. The cohort 10 
comprised all neonates with gestational age at birth < 34 weeks and at least one platelet count < 50x109/L. The 11 
NICU’s were located in the Leiden University Medical Center, Academic Medical Center Amsterdam, Máxima 12 
Medical Center Veldhoven, Isala Zwolle, Erasmus Medical Center Rotterdam, University Medical Center 13 
Utrecht and University Medical Center Groningen. We excluded patients with 1) severe congenital 14 
malformations; 2) a high suspicion of spurious platelet count (e.g. clots in the sample, or spontaneous platelet 15 
count recovery within six hours, or a platelet count labelled as spurious in the medical file); 3) thrombocytopenia 16 
occurring exclusively in the context of exchange transfusion; 4) prior admission to another NICU or 17 
readmission, and 5) major bleeding prior to severe thrombocytopenia. Neonates with major bleeding after end of 18 
follow up were not excluded, but registered as not having experienced major bleeding during the study. 19 
Selection of potential predictors 20 
We chose the predictors for our model prior to data analysis, under supervision of a professor of clinical 21 
epidemiology and head of clinical transfusion research center. Five experts (a paediatric hematologist and senior 22 
investigator with extensive experience in neonatal hematology studies, a pediatric hematologist and transfusion 23 
specialist in training, two neonatologist (of which one senior investigator with extensive experience in neonatal 24 
hematology studies) and a PhD student with an MD degree selected variables from a literature-based list of 25 
potential prognostic factors. The list was based on an large literature search yielding over 8000 abstracts. 360 26 
risk factors were identified from the abstracts and ranked according to number of publications per risk factor 27 
(Table SI). A variable was excluded from this list when it was not consistently documented in medical records, 28 
when few studies concerning this variable had been published, when a strong interaction with another variable 29 
was expected, when it was rare or too prevalent (occurring in <5% or >95% of our study population) or when the 30 
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variable was not measured routinely in clinical practice. All remaining risk factors (n=74) were further reviewed 1 
by the experts, who then voted for risk factors deemed to be good predictors for major bleeding. Based on the 2 
number of votes per risk factor we included the following variables in the model: gestational age, intra uterine 3 
growth retardation (IUGR), mechanical ventilation, platelet count, platelet transfusion, postnatal age at inclusion, 4 
and necrotizing enterocolitis (NEC) and/or sepsis (combined) (Table SII). Despite the lack of evidence for a 5 
direct causal assocation between platelet count and bleeding, platelet count was included, because  ultimately, 6 
our aim is to investigate which (if any) subgroups of neonates with thrombocytopenia benefit from platelet 7 
transfusions. Therefore it is essential for platelet count to be part of the prediction model. Platelet transfusion 8 
within the next two hours following the moment of bleeding risk prediction was included in the model to allow 9 
for calculation of two bleeding risks: one with and one without administration of a transfusion. NEC was defined 10 
as ≥ grade IIA as per Bell’s criteria.1 Sepsis was defined as culture positive sepsis or culture negative sepsis 11 
where antibiotics are given for a minimum of 5 complete days, to allow for use of the prediction model early in 12 
the course of sepsis, when culture results are not yet available. NEC and sepsis were combined because at onset, 13 
it is often difficult to distinguish between NEC and sepsis. Combining them allows for use of the prediction 14 
model despite this uncertainty.  15 
Main outcome definition 16 
The main outcome of this study was major bleeding, defined as either one of the following: 17 
1. Intraventricular hemorrhage (IVH) grade 3 (according to the Papile grading system);3 18 
2. IVH of any grade in combination with parenchymal involvement;  19 
3. Parenchymal hemorrhage (without IVH) visible on ultrasound scan;  20 
4. Cerebellar hemorrhage visible on ultrasound scan;  21 
5. Pulmonary hemorrhage, defined as fresh blood from the endotracheal tube in combination with 22 
increased ventilatory requirements; 23 
6. Any other type of hemorrhage, if major. A bleeding was considered major if it required or if it was 24 
associated with  either one of the following: a) red blood cell transfusion, b) volume boluses, c) need for 25 
inotropes (either start of inotrope therapy, or increased dose of current therapy), d) significant drop in 26 
blood pressure (mean blood pressure less than gestational age). 27 
Clinical practice in the seven participating centers 28 
In general, national protocols recommended that cranial ultrasound scans in preterm neonates were made on day 29 
of life 1, 3, 7 and then biweekly until discharge, and additional scans when clinically indicated. National platelet 30 
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transfusion protocols recommended transfusion at a platelet count threshold of 20x109/L. A higher threshold of 1 
50x109/L was recommended in case of active bleeding, surgery, after exchange transfusion, or for a clinically 2 
unstable neonate of <1500 grams and <32 weeks gestational age at birth. A threshold of 100x109/L was 3 
recommended prior to exchange transfusion. No national guidelines existed with regards to frequency of platelet 4 
count measurements, except for counts immediately prior to and within 24 hours after platelet transfusion. There 5 
was some variation in discharge policies between centers, depending on the presence of high care neonatal units 6 
in the vicinity of the NICU. 7 
Data acquisition 8 
Neonatologists, PhD students and medical students collected the data in an online GCP approved database. All 9 
received training to ensure data quality. We collected data from electronic and paper patient records on site. Start 10 
of the study (T0) was defined as the first moment at which platelet counts dropped <50x109/L . End of study was 11 
defined as the time of a major bleed, death or discharge/transfer, whichever occurred first. All events were 12 
recorded with date and time in hours and minutes. If the exact time of an event was unknown, an estimate was 13 
reported. We included neonates once their platelet count dropped below 50x109/L, and followed them for 10 14 
days, irrespective of their platelet counts. If they developed another episode of thrombocytopenia after these 10 15 
days, they were not re-included. Every ultrasound scan report was entered into the database. MRI results were 16 
not used to identify major bleeding, as only a small selected subset of neonates receives MRI scans, and 17 
ultrasound scans are generally considered to detect major bleeding accurately. Antepartum scan results were not 18 
recorded. We extracted platelet counts from the electronic hospital systems and checked for spurious platelet 19 
counts. Several hospitals provided electronic baseline data (e.g. GA, birth weight, date of birth, etc) from a 20 
national neonatal database, which we extracted and uploaded into the study database. We manually entered all 21 
additional clinical data. Discharge letters and ultrasound scan reports were screened for major hemorrhages.Site 22 
principal investigators reviewed the data concerning major bleeds to confirm accuracy of grading and timing.  23 
Sample size calculation 24 
Various studies showed bleeding incidences in premature neonates of 7-11%.4–7 Assuming an event rate of ten 25 
percent, and using an event per variable ratio of ten, we would need to include 100 neonates for each variables 26 
included in the model. Data were available from 7 NICU’s over a period of 5 years. Each year, 2800 neonates 27 
are admitted to the participating NICUs, of which approximately five percent have severe thrombocytopenia. 28 




The core research team drafted and approved a statistical analysis plan prior to data analysis. We developed a 1 
proportional baselines landmark supermodel, as described elsewhere, with bleeding within the next three days as 2 
outcome.8 At each two hour timepoint, all available data were entered into the model (Table SII). We used a full 3 
model approach and did not remove non-significant predictors.9 We included 7 main variables and an interaction 4 
term between platelet transfusion and platelet count, because we hypothesized that the association between 5 
platelet transfusions and bleeding may become stronger when platelet counts are lower. In order to test for time-6 
varying covariate effects, significant interactions between covariates and landmark times (both linear and 7 
quadratic) were also included in the model.  Missing data were replaced by missing indicators. With this 8 
predictionmodel, risk of bleeding at any time point within seven days could be calculated. Because the last 9 
model (at day seven) also predicts bleeding within three days, the total duration of follow up was ten days. 10 
Follow up was stopped after 10 days for two reasons: 1) we expected the number of neonates to develop major 11 
bleeding after more than 10 days of onset of thrombocytopenia to be low, and 2) after 10 days, many neonates 12 
would be discharged, and follow up would be very incomplete, hampering accurate analysis. 13 
We validated the model by internal calibration using the heuristic shrinkage factor by van Houwelingen et al.10 14 
When calculating bleeding risk probabilities from the model, we accounted for competing risk due to death using 15 
the Aalen-Johansen estimator.11 We did not correct for discharge or transfer, as we assumed that neonates who 16 
were discharged or transferred did not develop a major bleed. We performed various sensitivity analyses in order 17 
to test the robustness of the model. (Table SIII) 18 
We evaluated the model’s accuracy in correctly discriminating between patients with and without major bleeding 19 
using the dynamic cross-validated c-index. A c-index of 1.0 indicates perfect discrimination, while a c-index of 20 
0.5 is obtained when the model performs as well as chance. We calculated a c-index at each two hour timepoint, 21 
and reported this series of c-indices as a graph.  22 
Analyses were carried out using SPSS (version 24.0), Stata (version 14.1) and R (version 3.4.2). 23 
Clinical applicability of the model 24 
The process from initial prediction model development to implementation into clinical practice can be divided 25 
into multiple steps, as explained in the TRIPOD statement paper. The TRIPOD statement is a prediction model 26 
development checklist, which was endorsed by a large number of prominent medical journals.2 The first step 27 
(model development studies) is the development of a basic first model in a cohort. The next step is validation of 28 
this model in another cohort (model validation studies). Finally, the model needs to be tested in a randomized 29 
controlled trial (impact studies), because we cannot assume that prediction based treatment will invariably 30 
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improve outcome.12 Our study is a model development study. It is a first, basic prediction model for major 1 
bleeding in preterm neonates with severe thrombocytopenia. Due to the dynamic nature of the model, it cannot 2 
be fully summarized in one table, but once model validation studies have been performed, we will develop an 3 
online calculator. This calculator will perform the complex mathematical procedures required to convert the 4 
input of the seven variables into an absolute bleeding risk for a specific neonate at a specific time. We have 5 
chosen not to publish the calculator along with this paper, in order to prevent inappropriate premature use of the 6 
model in clinical practice. The model is available upon request for researchers looking to perform model 7 
validation and impact studies.  8 
Role of the funding source 9 
The funding source was not involved in the design, data collection, analyses and publication of this study. The 10 
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